Effect of Angiotensin-Converting Enzyme Inhibitors on Progression of Nondiabetic Renal Disease
Authors: Tazeen H. Jafar, Christopher H. Schmid, Andrew S. Levey
Journal: Annals of Internal Medicine (2002)

Letters20 August 2002Effect of Angiotensin-Converting Enzyme Inhibitors on Progression of Nondiabetic Renal DiseaseTazeen H. Jafar, MD, MPH, Christopher H. Schmid, PhD, and Andrew S. Levey, MDTazeen H. Jafar, MD, MPHThe Aga Khan University; Karachi, PakistanTufts University School of Medicine; Boston, MA 02111, Christopher H. Schmid, PhDThe Aga Khan University; Karachi, PakistanTufts University School of Medicine; Boston, MA 02111, and Andrew S. Levey, MDThe Aga Khan University; Karachi, PakistanTufts University School of Medicine; Boston, MA 02111Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-4-200208200-00026 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In our article on angiotensin-converting enzyme (ACE) inhibitors and progression of nondiabetic renal disease (1), we stated that regimens containing ACE inhibitors are more effective in slowing the progression of nondiabetic renal disease than regimens that do not include them. Drs. Schrier and Estacio, in their accompanying editorial (2), consider our findings "an exciting hypothesis that warrants confirmation" and state that meta-analysis cannot produce definitive conclusions. Others have concluded, however, that a well-conducted meta-analysis of randomized clinical trials of individual patient data provides the highest level of evidence in support of a therapeutic intervention (3).All of ...References1. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al . Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87. [PMID: 11453706] LinkGoogle Scholar2. Schrier RW, Estacio RO. The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials [Editorial]. Ann Intern Med. 2001;135:138-9. [PMID: 11453714] LinkGoogle Scholar3. Olkin I. Statistical and theoretical considerations in meta-analysis. J Clin Epidemiol. 1995; 48:133-46; discussion 147. [PMID: 7853039] Google Scholar Author, Article, and Disclosure InformationAuthors: Tazeen H. Jafar, MD, MPH; Christopher H. Schmid, PhD; Andrew S. Levey, MDAffiliations: The Aga Khan University; Karachi, PakistanTufts University School of Medicine; Boston, MA 02111 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease Tazeen H. Jafar , Christopher H. Schmid , Marcia Landa , Ioannis Giatras , Robert Toto , Giuseppe Remuzzi , Giuseppe Maschio , Barry M. Brenner , Annelise Kamper , Pietro Zucchelli , Gavin Becker , Andres Himmelmann , Kym Bannister , Paul Landais , Shahnaz Shahinfar , Paul E. de Jong , Dick de Zeeuw , Joseph Lau , Andrew S. Levey , and The Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal Disease: A Pooled Analysis of Individual-Patient Data from 11 Randomized, Controlled Trials Robert W. Schrier and Raymond O. Estacio Metrics Cited bySex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort StudyCongenital Optic Nerve AnomaliesOnline clinical pathway for chronic kidney disease management in primary care: a retrospective cohort studyCongenital Optic Nerve AnomaliesCongenital Optic Nerve AnomaliesAssociation of Specialist Physician Payment Model With Visit Frequency, Quality, and Costs of Care for People With Chronic DiseaseDeterminants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt NephropathySystemic lupus erythematosusThe Role of Primary Care in the Management of the Chronic Kidney Disease PopulationCardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration RateMahboob Rahman, MD, MS, Sara Pressel, MS, Barry R. Davis, MD, PhD, Chuke Nwachuku, MA, MPH, DrPH, Jackson T. Wright Jr., MD, PhD, Paul K. Whelton, MD, MSc, Joshua Barzilay, MD, Vecihi Batuman, MD, John H. Eckfeldt, MD, PhD, Michael A. Farber, MD, Stanley Franklin, MD, Mario Henriquez, MD, Nelson Kopyt, DO, Gail T. Louis, RN, Mohammad Saklayen, MD, Carole Stanford, MD, Candace Walworth, MD, Harry Ward, MD, and Thomas Wiegmann, MD, for the ALLHAT Collaborative Research Group*Progression of chronic kidney disease: Can it be prevented or arrested?An Angiotensin Receptor Blocker Reduces the Risk of Congestive Heart Failure in Elderly Hypertensive Patients with Renal InsufficiencyProteinuria and Microalbuminuria in Adults: Significance, Evaluation, and TreatmentResearch opportunities for reducing racial disparities in kidney disease 20 August 2002Volume 137, Issue 4Page: 298-299KeywordsACE inhibitorsAngiotensin converting enzymeAngiotensin converting enzyme inhibitorBlood pressurePatientsProteinuriaRenal diseases ePublished: 20 August 2002 Issue Published: 20 August 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...